Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death, and immune 21 checkpoint inhibitors (ICIs) have revolutionized its treatment by reactivating the immune system to tumor cells 1,2 . Despite significant improvements in patient outcomes, ICIs present 23 several key challenges: inconsistent efficacy across populations, complex resistance mechanisms, 24 and treatment-related toxicities 2,3
Liu et al. (Thu,) studied this question.